Study Of Perennial Allergic Rhinitis In Pediatrics

Overview

To verify of cetirizine dry syrup to ketotifen dry syrup in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period

Full Title of Study: “Evaluation of the Efficacy and Safety of Cetirizine Dry Syrup in Children -Suffering From Perennial Allergic Rhinitis-“

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double

Interventions

  • Drug: Cetirizine Dry Syrup

Clinical Trial Outcome Measures

Primary Measures

  • change in the total nasal symptom score (TNSS)

Secondary Measures

  • – Individual daily nasal symptom score – Investigator global improvement/patient global improvement – Nasal findings – Cetirizine serum concentrations – Adverse events

Participating in This Clinical Trial

Inclusion Criteria

  • Children with perennial allergic rhinitis. – Giving informed consent. – Children with a positive response to specific IgE antibody test. – Children assessed as positive in the nasal eosinophil count. – Children whose severity score of nasal symptom is 4 or higher. Exclusion criteria:

  • have spastic disease such as epilepsy – have a history of drug hypersensitivity – are pregnant, lactating or possibly pregnant female Children – are sensitive to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods – have vasomotor rhinitis and eosinophilic rhinitis – have asthma that requires the treatment with corticosteroid – have inappropriate complication of nasal disorder that may influence on the evaluation of the study drugs – have complicated with atopic dermatitis or urticaria that requires the treatment with antihistamine preparation – have started specific desensitization treatment or nonspecific modulation treatment but who have not reached the maintenance level of treatment – have received surgical treatment for reduction and modulation of nasal mucosa – redintegration therapy of nasal cavity to improve the degree of nasal airway – surgical operation to improve rhinorrhea.

Gender Eligibility: All

Minimum Age: 3 Years

Maximum Age: 14 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.